Table 3.

Estimated ORs and 95% CIs from multivariablea risk models for pancreatic cancer.

Clinical modelClinical/genetic modelClinical/genetic/biomarker model
Full follow-up period
 Model comparison (P valueb)3.24 × 10−86.03 × 10−5
 Model AUC0.610.650.67
 OR (95% CI)
  BMIc1.08 (0.97–1.21)1.07 (0.95–1.20)0.98 (0.86–1.10)
  WHRc1.13 (1.01–1.26)1.12 (1.00–1.26)1.08 (0.96–1.21)
  Physical activityc0.96 (0.86–1.06)0.95 (0.85–1.06)0.97 (0.86–1.08)
  Diagnosed diabetes (yes)2.10 (1.16–3.79)2.19 (1.19–4.02)1.70 (0.91–3.19)
  wGRSc1.37 (1.22–1.53)1.36 (1.21–1.52)
  Proinsulinc1.16 (1.03–1.31)
  Adiponectin (≥4.4 μg/mL)0.76 (0.58–0.99)
  IL6c1.10 (0.99–1.23)
  Total BCAAsc1.25 (1.04–1.51)
0–10 years of follow-up period
 Model comparison (P valueb)2.91 × 10−72.92 × 10−3
 Model AUC0.610.670.69
 OR (95% CI)
  BMIc1.05 (0.91–1.22)1.04 (0.90–1.21)0.96 (0.82–1.12)
  WHRc1.08 (0.93–1.25)1.06 (0.91–1.23)1.00 (0.86–1.17)
  Physical activityc0.86 (0.74–1.00)0.86 (0.74–1.01)0.88 (0.75–1.03)
  Diagnosed diabetes (yes)2.22 (1.09–4.54)2.14 (1.02–4.50)1.65 (0.77–3.56)
  wGRSc1.44 (1.25–1.67)1.43 (1.23–1.65)
  Proinsulinc1.10 (0.94–1.27)
  Adiponectin (≥4.4 μg/mL)0.70 (0.48–1.02)
  IL6c1.13 (0.98–1.30)
  Total BCAAsc1.24 (1.00–1.54)
  • aAdjusted for matching factors, age, cohort (also gender), race/ethnicity, smoking status, fasting status, and month/year of blood collection.

  • bP value was estimated from the likelihood ratio test comparing the clinical/genetic model to the clinical model and the clinical/genetic/biomarker model to the clinical/genetic model.

  • cStandardized variables with mean = 0 and SD = 1 within each cohort.